gevokizumab
mAbexperimental
Gevokizumab is an experimental monoclonal antibody, developed by XOMA Corporation, with allosteric modulating properties. Gevokizumab binds to interleukin-1 beta, a pro-inflammatory cytokine, and downmodulates the cellular signaling events that produce inflammation. IL-1 beta has been implicated in cardiovascular conditions, lung cancer, and auto-inflammatory diseases. — Wikipedia
Clinical trial activity
26 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
23
Phase 3
9
Phase 4
0
Earliest trial started Jul 1, 2007 (NCT00513214)
Timeline
Indications
Studied for
- Acne Vulgaris · Phase 2
- Arthritis, Rheumatoid · Phase 2
- Autoimmune Diseases · Phase 2
- Behcet Syndrome · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 1
- Cryopyrin-Associated Periodic Syndromes · Phase 1/Phase 2
- Diabetes Mellitus, Type 1 · Phase 2
- Diabetes Mellitus, Type 2 · Phase 2
- Esophageal Neoplasms · Phase 1
- Hypoglycemia · Phase 2
- Inflammation · Phase 1/Phase 2
- Osteoarthritis · Phase 2
- Pyoderma Gangrenosum · Phase 3
- Uveitis · Phase 3
Mechanism of action
- Interleukin-1 betaINHIBITOR
IL1B inhibitor
- Interleukin-1 betaNEGATIVE ALLOSTERIC MODULATOR
IL1B negative allosteric modulator
Potent anti-IL-1ß neutralizing antibody. Binds to a unique IL-1ß epitope that is proximal to, but does not overlap with the receptor/ligand interface.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGevokizumab ↗
- ChEMBLCHEMBL1743026 ↗
Also known as
- gevokizumab
- gevokizumab
- gevokizumab
- gevokizumab
- xma 005.2
- xma-005.2
- xma005.2
- xoma052
- xoma 052
- xoma 052
- xoma-052
- xoma-052
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05178576 | Phase 2 | Jun 24, 2022 | Natera, Inc., Novartis, NSABP Foundation |
| NCT03798626 | Phase 1 | May 22, 2019 | Novartis |
| NCT02772718 | Phase 2 | Apr 1, 2016 | Xoma |
| NCT02326740 | Phase 3 | Dec 1, 2014 | Xoma |
| NCT02258867 | Phase 3 | Nov 1, 2014 | Xoma |
| NCT02315417 | Phase 3 | Nov 1, 2014 | Xoma |
| NCT02318914 | Phase 3 | Nov 1, 2014 | Xoma |
| NCT02375685 | Phase 3 | Aug 1, 2014 | Servier |
| NCT02258854 | Phase 3 | Mar 1, 2014 | Xoma |
| NCT01950312 | Phase 2 | Aug 1, 2013 | Feinstein Institute for Medical Research, National Institute on Deafness and Other Communication Disorders (NIDCD), Xoma |
| NCT01882504 | Phase 2 | May 1, 2013 | Xoma |
| NCT01882491 | Phase 2 | May 1, 2013 | Xoma |
| NCT02293564 | N/A | Mar 1, 2013 | Xoma |
| NCT01965145 | Phase 3 | Nov 1, 2012 | Servier, Yonsei University |
| NCT01747538 | Phase 3 | Oct 1, 2012 | Servier, Xoma |
| NCT01684345 | Phase 3 | Aug 1, 2012 | Servier, Xoma |
| NCT01683396 | Phase 2 | Jul 1, 2012 | Xoma |
| NCT01498874 | Phase 2 | Dec 1, 2011 | Xoma |
| NCT01211977 | Phase 1/Phase 2 (Phase 2) | Aug 27, 2010 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
| NCT01144975 | Phase 2 | May 1, 2010 | Xoma |
Showing 20 of 26 trials
Page 1 / 2
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xoma | For profit | 21 | 20 | 4 | 2007 |
| Servier | For profit | 4 | 2 | 1 | 2012 |
| University of Zurich | Academic/Hospital | 3 | 1 | 2 | 2007 |
| Novartis | For profit | 2 | 1 | 2 | 2019 |
| Feinstein Institute for Medical Research | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Juvenile Diabetes Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Natera, Inc. | For profit | 1 | 0 | 1 | 2022 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Government | 1 | 1 | 1 | 2010 |
| National Institute on Deafness and Other Communication Disorders (NIDCD) | Government | 1 | 0 | 1 | 2013 |
| NSABP Foundation | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Bern | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Yonsei University | Academic/Hospital | 1 | 0 | 1 | 2012 |
12 organizations
Page 1 / 1